Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBI 226 in facial acne vulgaris
NCT00211497Phase 2Completed
- Sponsor
- BioWest Therapeutics
- Start
- Jan 2003
- Modality
- Peptides, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of omiganan in acne vulgaris (3 arms), sponsored by BioWest Therapeutics. Primary endpoint: Percent change from Baseline to Week 12 in inflammatory acne lesion counts. Started Jan 2003; status: completed.
02
Drugs
omiganan
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT00211497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00211497.